{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:04:47Z","timestamp":1768417487713,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s12325-023-02748-y","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T18:01:55Z","timestamp":1704218515000},"page":"744-758","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir\/Pibrentasvir in Patients with Hepatitis\u00a0C and Cirrhosis"],"prefix":"10.1007","volume":"41","author":[{"given":"Mei","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loralee B.","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Melkonian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheri","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihe G.","family":"Daida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"6","key":"2748_CR1","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.jhep.2020.01.025","volume":"72","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Carrion JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112\u201321.","journal-title":"J Hepatol"},{"key":"2748_CR2","unstructured":"US Food and Drug Administration. Mavret Summary Review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209394Orig1s000SumR.pdf. Accessed 1 May\u00a02023."},{"key":"2748_CR3","unstructured":"US Food and Drug Administration. Mavret: Label for New Patient Population. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209394s006lbl.pdf. Accessed May\u00a01, 2023."},{"issue":"3","key":"2748_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown Jr","year":"2020","unstructured":"Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir\/pibrentasvir for 8\u00a0weeks in treatment-naive patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: the EXPEDITION-8 trial. J Hepatol. 2020;72(3):441\u20139.","journal-title":"J Hepatol"},{"key":"2748_CR5","unstructured":"US Food and Drug Administration. Mavyret Labeling Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209394s010lbl.pdf. Published 2020. Accessed 2023."},{"key":"2748_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-023-10506-z","author":"TS Chang","year":"2023","unstructured":"Chang TS, Huang CF, Kuo HT, et al. Effectiveness and safety of 8-week glecaprevir\/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry. Hepatol Int. 2023. https:\/\/doi.org\/10.1007\/s12072-023-10506-z.","journal-title":"Hepatol Int"},{"issue":"5","key":"2748_CR7","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1007\/s12325-020-01301-5","volume":"37","author":"SL Flamm","year":"2020","unstructured":"Flamm SL, Kort J, Marx SE, et al. Effectiveness of 8-week glecaprevir\/pibrentasvir for treatment-naive, compensated cirrhotic patients with chronic hepatitis\u00a0C infection. Adv Ther. 2020;37(5):2267\u201374.","journal-title":"Adv Ther"},{"issue":"7","key":"2748_CR8","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s40121-023-00823-z","volume":"12","author":"N Reau","year":"2023","unstructured":"Reau N, Cheng WH, Shao Q, Marx SE, Brooks H, Martinez A. Real-world effectiveness of 8-week glecaprevir\/pibrentasvir in treatment-na\u00efve, compensated cirrhotic HCV patients. Infect Dis Ther. 2023;12(7):1849\u201360.","journal-title":"Infect Dis Ther"},{"issue":"S1","key":"2748_CR9","first-page":"417A","volume":"68","author":"PST Belperio","year":"2018","unstructured":"Belperio PST, Loomis T, Mole L, Backus L. Real-world effectiveness of glecaprevir\/pibrentasvir in 1,941 patients with hepatitis\u00a0C genotypes 1 through 4. Hepatology. 2018;68(S1):417A.","journal-title":"Hepatology"},{"issue":"1","key":"2748_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/cid\/cis815","volume":"56","author":"AC Moorman","year":"2013","unstructured":"Moorman AC, Gordon SC, Rupp LB, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the chronic hepatitis cohort study. Clin Infect Dis. 2013;56(1):40\u201350.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2748_CR11","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1007\/s10620-014-3272-6","volume":"59","author":"M Lu","year":"2014","unstructured":"Lu M, Rupp LB, Moorman AC, et al. Comparative effectiveness research of chronic hepatitis B and C cohort study (CHeCS): improving data collection and cohort identification. Dig Dis Sci. 2014;59(12):3053\u201361.","journal-title":"Dig Dis Sci"},{"key":"2748_CR12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2147\/CLEP.S262558","volume":"12","author":"M Lu","year":"2020","unstructured":"Lu M, Bowlus CL, Lindor K, et al. Validity of an automated algorithm to identify cirrhosis using electronic health records in patients with primary biliary cholangitis. Clin Epidemiol. 2020;12:1261\u20137.","journal-title":"Clin Epidemiol"},{"issue":"6","key":"2748_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"2748_CR14","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/jvh.13162","volume":"26","author":"M Lu","year":"2019","unstructured":"Lu M, Wu KH, Li J, et al. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis\u00a0C patients at risk of treatment failure. J Viral Hepatitis. 2019;26(10):1210\u20137.","journal-title":"J Viral Hepatitis"}],"updated-by":[{"DOI":"10.1007\/s12325-024-02858-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02748-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02748-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02748-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T07:15:51Z","timestamp":1712819751000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02748-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02748-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-024-02858-1","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"17 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-024-02858-1","URL":"https:\/\/doi.org\/10.1007\/s12325-024-02858-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stuart C. Gordon receives grant\/research support from AbbVie Pharmaceuticals, CymaBay, Genfit, Gilead Sciences, GlaxoSmithKline, Intercept Pharmaceuticals, and Viking Therapeutics. Mei Lu and Loralee B. Rupp receive research grant support from GlaxoSmithKline, AbbVie, and Intercept Pharmaceuticals. Yihe G. Daida receives research support from GlaxoSmithKline, Sanofi and Vir Biotech. Mark A. Schmidt receives research support from GlaxoSmithKline and Intercept Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study follows all Declaration of Helsinki and US Department of Health and Human Services guidelines regarding the protection of human subjects. The CHeCS protocol was approved and is renewed annually by the institutional review boards (IRB) at each of the four sites (Henry Ford Health [HFH], Detroit, MI; Geisinger Health System [GHS], Danville, PA; Kaiser Permanente Northwest, Portland, OR; and Kaiser Permanente Hawaii, Honolulu, HI). The overarching CHeCS study protocol was approved by the HFH IRB (IORG0000148). Due to the de-identified nature of this observational study, requirements for written informed consent were waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}